Me level of cellular response as the low dose groups (Fig.

Me level of cellular response as the low dose groups (Fig. 4). It is noteworthy that the number of inoculations did not influence the strength of the immune response at low PA-MSHA doses (102, 104 CFU), while three inoculations of high dose PA-MSHA resulted in significantly greater responses compared with two inoculations of 108 CFU PA-MSHA. The exact cause and mechanism for this immunosuppressive effect is currently not understood. The ICS results showed the same tendency as the ELISPOT results (shown in Fig. S1). These results clearly demonstrated that the two-inoculation DNA vaccine strategy resulted in active and robust HIV-specific immunological response when co-administered with low dose PA-MSHA.Low dose PA-MSHA HDAC-IN-3 site enhanced DNA vaccine-induced HIV Env-specific humoral immune responseHumoral immune responses play an essential role in defending against infection. Here, PA-MSHA could not promote the HIV-1 Env-specific antibody response in two inoculations regimen (Fig. 5A), and IgG isotype study showed all groups induced balanced Th1/Th2 responses (Fig. 5C). However, low dose PAMSHA (102 CFU) significantly increased HIV specific antibody titer (Fig. 5B), in comparison with others PA-MHSA doses in the three-inoculation regimen. High dose PA-MSHA (108 CFU) still showed poor ability to induce humoral responses, but the IgGP. aeruginosa Enhanced DNA Vaccine ImmunoreactivityP. aeruginosa Enhanced DNA Vaccine ImmunoreactivityFigure 1. Heat map of the expression of TLR pathway 25837696 genes after stimulation with PA-MSHA at different time points. Up-regulation was defined as a 3-fold increase as compared with negative control, and down-regulation as a #3-fold decrease. doi:10.1371/journal.pone.0047724.gisotype results indicated 108 CFU PA-MSHA induced Th2-bias immunity responses (Fig. 5D).Low dose PA-MSHA promoted antibody avidity of mouse Env antiserumAntibody avidity was assessed using sodium thiocyanate (NaSCN)-displacement ELISA was used to evaluate the avidity of the antibody [32,33,34,35], in which graded concentrations of NaSCN were used to disrupt the PD168393 antigen-antibody interaction. The effective concentration of NaSCN required to release 50 of antibodies (ED50) from binding is higher for antibodies with stronger avidity for their antigens. ED50 for antibodies collected from mice two weeks after the most recent vaccination with DNA alone was ,2.0 M, higher than DNA co-immunization with PA-MSHA in the two-inoculation groups (Fig. 6A). In contrast, in the three-inoculation strategy, the ED50 of DNA co-vaccination with 102 CFU PA-MSHA was ,3.2 M (Fig. 6B), higher than other groups. NaSCN-displacement ELISA demonstrated the advantage of promoting antibody maturation in the three-inoculation strategy with 102 CFU PAMSHA (Fig. 6B). However, low dose PA-MSHA is capable of inducing both robust humoral immune response and high avidity antibody in the three-inoculation strategy and may serve as the best adjuvant strategy.DiscussionIn this study, we assessed the ability of PA-MSHA to activate innate immune responses in murine splenocytes and BMDCs, as well as its in vivo adjuvant effects in enhancing cellular and humoral immune responses to HIV-1 Env peptides following co-administration with a DNA vaccine. PA-MSHA enabled activation of theTLR pathway mediated by NF-kB and JNK signaling in splenocytes, and promoted the up-regulation of co-stimulatory molecule CD86 in BMDCs. As well, co-inoculation of the DNA vaccine with low dosages (102?04 CFU) of PA-MSH.Me level of cellular response as the low dose groups (Fig. 4). It is noteworthy that the number of inoculations did not influence the strength of the immune response at low PA-MSHA doses (102, 104 CFU), while three inoculations of high dose PA-MSHA resulted in significantly greater responses compared with two inoculations of 108 CFU PA-MSHA. The exact cause and mechanism for this immunosuppressive effect is currently not understood. The ICS results showed the same tendency as the ELISPOT results (shown in Fig. S1). These results clearly demonstrated that the two-inoculation DNA vaccine strategy resulted in active and robust HIV-specific immunological response when co-administered with low dose PA-MSHA.Low dose PA-MSHA enhanced DNA vaccine-induced HIV Env-specific humoral immune responseHumoral immune responses play an essential role in defending against infection. Here, PA-MSHA could not promote the HIV-1 Env-specific antibody response in two inoculations regimen (Fig. 5A), and IgG isotype study showed all groups induced balanced Th1/Th2 responses (Fig. 5C). However, low dose PAMSHA (102 CFU) significantly increased HIV specific antibody titer (Fig. 5B), in comparison with others PA-MHSA doses in the three-inoculation regimen. High dose PA-MSHA (108 CFU) still showed poor ability to induce humoral responses, but the IgGP. aeruginosa Enhanced DNA Vaccine ImmunoreactivityP. aeruginosa Enhanced DNA Vaccine ImmunoreactivityFigure 1. Heat map of the expression of TLR pathway 25837696 genes after stimulation with PA-MSHA at different time points. Up-regulation was defined as a 3-fold increase as compared with negative control, and down-regulation as a #3-fold decrease. doi:10.1371/journal.pone.0047724.gisotype results indicated 108 CFU PA-MSHA induced Th2-bias immunity responses (Fig. 5D).Low dose PA-MSHA promoted antibody avidity of mouse Env antiserumAntibody avidity was assessed using sodium thiocyanate (NaSCN)-displacement ELISA was used to evaluate the avidity of the antibody [32,33,34,35], in which graded concentrations of NaSCN were used to disrupt the antigen-antibody interaction. The effective concentration of NaSCN required to release 50 of antibodies (ED50) from binding is higher for antibodies with stronger avidity for their antigens. ED50 for antibodies collected from mice two weeks after the most recent vaccination with DNA alone was ,2.0 M, higher than DNA co-immunization with PA-MSHA in the two-inoculation groups (Fig. 6A). In contrast, in the three-inoculation strategy, the ED50 of DNA co-vaccination with 102 CFU PA-MSHA was ,3.2 M (Fig. 6B), higher than other groups. NaSCN-displacement ELISA demonstrated the advantage of promoting antibody maturation in the three-inoculation strategy with 102 CFU PAMSHA (Fig. 6B). However, low dose PA-MSHA is capable of inducing both robust humoral immune response and high avidity antibody in the three-inoculation strategy and may serve as the best adjuvant strategy.DiscussionIn this study, we assessed the ability of PA-MSHA to activate innate immune responses in murine splenocytes and BMDCs, as well as its in vivo adjuvant effects in enhancing cellular and humoral immune responses to HIV-1 Env peptides following co-administration with a DNA vaccine. PA-MSHA enabled activation of theTLR pathway mediated by NF-kB and JNK signaling in splenocytes, and promoted the up-regulation of co-stimulatory molecule CD86 in BMDCs. As well, co-inoculation of the DNA vaccine with low dosages (102?04 CFU) of PA-MSH.